{"id":"https://openalex.org/W7128250876","doi":"https://doi.org/10.1158/1078-0432.c.7981435","title":"Data from A Phase I Dose Escalation and Cohort Expansion Study of CB307, a Trispecific Humabody against PSMA, CD137, and Albumin in Patients with PSMA-Positive Solid Tumors","display_name":"Data from A Phase I Dose Escalation and Cohort Expansion Study of CB307, a Trispecific Humabody against PSMA, CD137, and Albumin in Patients with PSMA-Positive Solid Tumors","publication_year":2025,"publication_date":"2025-08-14","ids":{"openalex":"https://openalex.org/W7128250876","doi":"https://doi.org/10.1158/1078-0432.c.7981435"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.c.7981435","doi":"https://doi.org/10.1158/1078-0432.c.7981435","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.7981435","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/1078-0432.c.7981435","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5072378199","display_name":"Johann Sebastian De Bono","orcid":"https://orcid.org/0000-0002-2034-595X","observed_orcids":["https://orcid.org/0000-0002-2034-595X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Johann S. de Bono","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-2034-595X","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068416680","display_name":"Anja Williams","orcid":"https://orcid.org/0000-0002-4944-1558","observed_orcids":["https://orcid.org/0000-0002-4944-1558"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anja Williams","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-4944-1558","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029243551","display_name":"Ignacio Melero","orcid":"https://orcid.org/0000-0002-1360-348X","observed_orcids":["https://orcid.org/0000-0002-1360-348X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ignacio Melero","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-1360-348X","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008796630","display_name":"Anuradha Jayaram","orcid":"https://orcid.org/0000-0002-5255-8909","observed_orcids":["https://orcid.org/0000-0002-5255-8909"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anuradha Jayaram","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-5255-8909","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011263550","display_name":"Jessica E. Hawley","orcid":"https://orcid.org/0000-0003-1720-5654","observed_orcids":["https://orcid.org/0000-0003-1720-5654"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jessica E. Hawley","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-1720-5654","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029689781","display_name":"Bernard Doger de Sp\u00e9ville","orcid":"https://orcid.org/0009-0004-3264-5433","observed_orcids":["https://orcid.org/0009-0004-3264-5433"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Bernard Doger de Speville","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0004-3264-5433","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070663284","display_name":"Irene Moreno","orcid":"https://orcid.org/0000-0001-5027-6388","observed_orcids":["https://orcid.org/0000-0001-5027-6388"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Irene Moreno","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-5027-6388","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024147987","display_name":"Daniel Castellano","orcid":"https://orcid.org/0000-0002-9106-0687","observed_orcids":["https://orcid.org/0000-0002-9106-0687"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Daniel Castellano","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-9106-0687","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5096599515","display_name":"\u00d2scar Ribas Reig","orcid":"https://orcid.org/0000-0003-1166-6943","observed_orcids":["https://orcid.org/0000-0003-1166-6943"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"\u00d2scar Reig","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-1166-6943","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087511051","display_name":"Daan G. Knapen","orcid":"https://orcid.org/0000-0002-2523-137X","observed_orcids":["https://orcid.org/0000-0002-2523-137X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Daan G. Knapen","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-2523-137X","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080995417","display_name":"Ge\u00f2rgia Anguera","orcid":"https://orcid.org/0000-0002-6060-1110","observed_orcids":["https://orcid.org/0000-0002-6060-1110"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Georgia Anguera","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-6060-1110","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5125293305","display_name":"Julia Martinez","orcid":"https://orcid.org/0000-0003-0634-4974","observed_orcids":["https://orcid.org/0000-0003-0634-4974"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Julia Martinez","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-0634-4974","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077963608","display_name":"Eelke Hiddo Gort","orcid":"https://orcid.org/0000-0001-7390-0761","observed_orcids":["https://orcid.org/0000-0001-7390-0761"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Eelke Gort","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-7390-0761","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5125311926","display_name":"Maja de Jonge","orcid":"https://orcid.org/0000-0002-1938-226X","observed_orcids":["https://orcid.org/0000-0002-1938-226X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Maja de Jonge","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-1938-226X","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101633513","display_name":"Jos\u00e9 Luis Alonso-Romero","orcid":"https://orcid.org/0000-0001-8746-2096","observed_orcids":["https://orcid.org/0000-0001-8746-2096"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jose Luis Alonso-Romero","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-8746-2096","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020352800","display_name":"Valentina Boni","orcid":"https://orcid.org/0000-0002-8675-0018","observed_orcids":["https://orcid.org/0000-0002-8675-0018"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Valentina Boni","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-8675-0018","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017006773","display_name":"Jose Luis Perez-Gracia","orcid":"https://orcid.org/0000-0003-4941-9075","observed_orcids":["https://orcid.org/0000-0003-4941-9075"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jose Luis Perez-Gracia","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-4941-9075","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5125288332","display_name":"Alejandro Falcon","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alejandro Falcon","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-4531-5877","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053970291","display_name":"Derk Jan A. de Groot","orcid":"https://orcid.org/0000-0002-8306-6835","observed_orcids":["https://orcid.org/0000-0002-8306-6835"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Derk Jan de Groot","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-8306-6835","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082781519","display_name":"Andrew J. Pierce","orcid":"https://orcid.org/0000-0001-9062-0307","observed_orcids":["https://orcid.org/0000-0001-9062-0307","https://orcid.org/0000-0003-0942-0370","https://orcid.org/0000-0002-0738-2756"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Andrew J. Pierce","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-9062-0307","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068519558","display_name":"Andrew J. Leishman","orcid":"https://orcid.org/0000-0003-4273-8188","observed_orcids":["https://orcid.org/0000-0003-4273-8188"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Andrew J. Leishman","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-4273-8188","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112508130","display_name":"Peter M. Lloyd","orcid":"https://orcid.org/0009-0007-2337-7459","observed_orcids":["https://orcid.org/0009-0007-2337-7459"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Peter Lloyd","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0007-2337-7459","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001950272","display_name":"Phillip D. Bartlett","orcid":"https://orcid.org/0000-0002-2016-944X","observed_orcids":["https://orcid.org/0000-0002-2016-944X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Phillip D. Bartlett","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-2016-944X","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021136090","display_name":"Philip A Bland-Ward","orcid":"https://orcid.org/0009-0005-7126-0699","observed_orcids":["https://orcid.org/0009-0005-7126-0699"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Philip Bland-Ward","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0005-7126-0699","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5115864998","display_name":"Albert Chau","orcid":"https://orcid.org/0000-0002-5141-1710","observed_orcids":["https://orcid.org/0000-0002-5141-1710"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Albert Chau","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-5141-1710","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5125331658","display_name":"Minjung Song","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Minjung Song","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5114043124","display_name":"Kevin Duffy","orcid":"https://orcid.org/0009-0000-6246-5901","observed_orcids":["https://orcid.org/0009-0000-6246-5901"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kevin Duffy","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0000-6246-5901","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074024725","display_name":"Kenji Hashimoto","orcid":"https://orcid.org/0000-0001-8826-2037","observed_orcids":["https://orcid.org/0000-0001-8826-2037"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kenji Hashimoto","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-8826-2037","affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5125319681","display_name":"Elisabeth de Vries","orcid":"https://orcid.org/0000-0002-8949-7425","observed_orcids":["https://orcid.org/0000-0002-8949-7425"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Elisabeth de Vries","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-8949-7425","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.4918999969959259,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.4918999969959259,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11395","display_name":"Radiopharmaceutical Chemistry and Applications","score":0.19480000436306,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.11959999799728394,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/trispecific-antibodies","display_name":"trispecific antibodies","score":0.8700000047683716},{"id":"https://openalex.org/keywords/prostate-specific-membrane-antigen","display_name":"prostate-specific membrane antigen","score":0.9309999942779541},{"id":"https://openalex.org/keywords/4-1bb","display_name":"4-1BB","score":0.9639999866485596},{"id":"https://openalex.org/keywords/human-serum-albumin","display_name":"human serum albumin","score":0.8539999723434448},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.8240000009536743},{"id":"https://openalex.org/keywords/castration-resistant-prostate-cancer","display_name":"castration-resistant prostate cancer","score":0.9259999990463257},{"id":"https://openalex.org/keywords/hepatotoxicity","display_name":"hepatotoxicity","score":0.8659999966621399},{"id":"https://openalex.org/keywords/elevated-liver-enzymes","display_name":"elevated liver enzymes","score":0.9300000071525574},{"id":"https://openalex.org/keywords/t-cell-activation","display_name":"T cell activation","score":0.5979999899864197},{"id":"https://openalex.org/keywords/pd-l1-expression","display_name":"PD-L1 expression","score":0.9369999766349792},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.41200000047683716},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.7139999866485596},{"id":"https://openalex.org/keywords/combination-immunotherapy","display_name":"combination immunotherapy","score":0.6110000014305115}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8697999715805054},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.7638999819755554},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.6467000246047974},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5995000004768372},{"id":"https://openalex.org/C2776999253","wikidata":"https://www.wikidata.org/wiki/Q1304270","display_name":"Combination therapy","level":2,"score":0.5720000267028809},{"id":"https://openalex.org/C2779984678","wikidata":"https://www.wikidata.org/wiki/Q2145898","display_name":"Response Evaluation Criteria in Solid Tumors","level":4,"score":0.4131999909877777},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4011000096797943},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4011000096797943},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3928000032901764},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.3849000036716461},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.38109999895095825},{"id":"https://openalex.org/C2776125364","wikidata":"https://www.wikidata.org/wiki/Q169219","display_name":"Albumin","level":2,"score":0.3783000111579895},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3614000082015991},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.35519999265670776},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.3199999928474426},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3107999861240387},{"id":"https://openalex.org/C2777513400","wikidata":"https://www.wikidata.org/wiki/Q104219","display_name":"Bilirubin","level":2,"score":0.30090001225471497},{"id":"https://openalex.org/C3019864225","wikidata":"https://www.wikidata.org/wiki/Q5867482","display_name":"Combination chemotherapy","level":3,"score":0.3003999888896942},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.290800005197525},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.2906000018119812},{"id":"https://openalex.org/C167135981","wikidata":"https://www.wikidata.org/wiki/Q2146302","display_name":"Retrospective cohort study","level":2,"score":0.28769999742507935},{"id":"https://openalex.org/C2780192828","wikidata":"https://www.wikidata.org/wiki/Q181257","display_name":"Prostate cancer","level":3,"score":0.2831000089645386},{"id":"https://openalex.org/C2778822529","wikidata":"https://www.wikidata.org/wiki/Q1951525","display_name":"Progressive disease","level":3,"score":0.25999999046325684},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.25049999356269836}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1078-0432.c.7981435","doi":"https://doi.org/10.1158/1078-0432.c.7981435","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.7981435","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.c.7981435","doi":"https://doi.org/10.1158/1078-0432.c.7981435","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.7981435","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4408505308","https://openalex.org/W4282972761","https://openalex.org/W4402560037","https://openalex.org/W4394622725","https://openalex.org/W4394818360","https://openalex.org/W3178266205","https://openalex.org/W4232719427","https://openalex.org/W4282964855","https://openalex.org/W7160612293","https://openalex.org/W4393087063"],"abstract_inverted_index":{"AbstractPurpose:":[0],"CB307":[1,51,78,86,91,101,107,180,213,246,260,271],"is":[2,20],"a":[3,223,276],"trispecific":[4],"variable":[5],"heavy-chain":[6],"antibody":[7],"fragment":[8],"against":[9],"prostate-specific":[10],"membrane":[11],"antigen":[12],"(PSMA),":[13],"CD137,":[14],"and":[15,33,48,60,83,95,149,157,182,194,216,267,278,283,300],"human":[16],"serum":[17],"albumin.":[18],"It":[19],"designed":[21],"to":[22,34,104,244],"mitigate":[23],"hepatotoxicity":[24],"by":[25,298],"activating":[26],"T":[27],"cells":[28],"only":[29],"in":[30,55,73,89,96,120,145,151,167,176,183,186,206,209,218,232,239,265,279,288],"PSMA-positive":[31,68],"tumors":[32,70,266],"increase":[35],"drug":[36],"half-life":[37],"through":[38],"albumin":[39],"binding.":[40],"This":[41],"phase":[42,76],"I":[43],"study":[44],"investigated":[45],"the":[46,74,90,146,152,177,187,210,219,227,240],"safety":[47,82],"tolerability":[49],"of":[50,77,85,138,202],"as":[52,114,275],"monotherapy":[53,92,115,147,181,214,277],"or":[54,119],"combination":[56,97,121,153,188,220,280],"with":[57,67,98,122,170,281,290],"pembrolizumab.":[58,99],"Patients":[59,62],"Methods:":[61],"who":[63,234],"were":[64,71,87,134,155,165,286],"heavily":[65],"pretreated":[66],"solid":[69],"enrolled":[72,175,208],"dose-escalation":[75],"monotherapy.":[79],"The":[80],"additional":[81],"efficacy":[84],"assessed":[88],"expansion":[93,264],"cohort":[94,148,189,215],"Results:":[100],"was":[102,108,204,229,272],"administered":[103],"75":[105],"patients.":[106],"given":[109],"once":[110],"every":[111],"7":[112],"days":[113],"(N":[116,124],"=":[117,125,248,251,255,258],"50)":[118],"pembrolizumab":[123],"25).":[126],"Two":[127],"dose-limiting":[128],"toxicities":[129],"(grade":[130],"3":[131,141],"transient":[132],"transaminitis)":[133],"observed.":[135],"A":[136,197],"total":[137],"three":[139],"grade":[140],"transaminitis":[142],"events":[143],"(one":[144],"two":[150,168],"cohort)":[154],"observed,":[156],"none":[158],"involved":[159],"bilirubin":[160],"elevation.":[161],"Durable":[162],"RECIST":[163],"responses":[164,285],"observed":[166,205,287],"patients":[169,207,233,289],"metastatic":[171,291],"castration-resistant":[172,292],"prostate":[173,293],"cancer":[174],"800":[178,211],"mg":[179,212],"one":[184],"patient":[185],"(overall":[190],"response":[191,228],"rates:":[192],"11.1%":[193],"7.1%,":[195],"respectively).":[196],"disease":[198],"control":[199],"rate":[200],"(DCR)":[201],"50%":[203],"42.9%":[217],"cohort.":[221],"In":[222],"post":[224],"hoc":[225],"analysis,":[226],"numerically":[230],"better":[231],"had":[235],"not":[236],"received":[237],"chemotherapy":[238],"6":[241],"months":[242],"prior":[243],"starting":[245],"(ORR":[247],"20%,":[249],"DCR":[250,257],"60%":[252],"vs.":[253],"ORR":[254],"0%,":[256],"37.5%).":[259],"induces":[261],"cytotoxic":[262],"cell":[263],"PD-L1":[268],"expression.":[269],"Conclusions:":[270],"well":[273],"tolerated":[274],"pembrolizumab,":[282],"tumor":[284],"cancer.":[294],"See":[295],"related":[296],"commentary":[297],"Nguyen":[299],"Luke,":[301],"p.":[302],"3356":[303]},"counts_by_year":[],"updated_date":"2026-11-09T13:22:03.289127","created_date":"2026-02-08T00:00:00"}